Tysabri Impacts Seroconversion in John Cunningham Virus

This article originally appeared here.
Share this content:
Tysabri Impacts Seroconversion in John Cunningham Virus
Tysabri Impacts Seroconversion in John Cunningham Virus

THURSDAY, Jan. 28, 2016 (HealthDay News) -- For patients with John Cunningham virus (JCV), natalizumab (Tysabri) treatment affects seroconversion and JCV index values, according to a study published online Jan. 27 in Neurology: Neuroimmunology & Neuroinflammation.

Nicholas Schwab, Ph.D., from the University of Münster in Germany, and colleagues analyzed JCV serology in natalizumab-treated patients over time. Data were included for 1,921 German patients and 1,259 French patients.

The researchers found that over 14.8 months, JCV serostatus changed in 69 of 525 longitudinally followed German patients (13.1 percent). Per year, 10.3 percent of 399 initially JCV− German patients and 8.5 percent of initially JCV− French patients had seroconversion according to serostatus. JCV index values could be reproduced (R² = 0.89) with 16 percent of samples being set into different risk categories between two assessments. There was an increase in the index values of JCV+ patients over time (P = 0.009), which was not attributed to aging. In 14.8 months, natalizumab treatment correlated with a 15.9 percent increase of value in JCV+ patients (12.9 percent per year).

"JCV seroconversion and index values may be influenced by treatment with natalizumab," the authors write. "It is therefore important to monitor patients' JCV serology but also to incorporate additional risk factors into the progressive multifocal leukoencephalopathy risk stratification."

Several authors disclosed financial ties to the biopharmaceutical industry.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Improved achievement of glycemic targets, reduced body weight

European, American Guidelines Lead to Different Recs for Statins

European, American Guidelines Lead to Different Recs for ...

Quantification of CAC score can improve stratification for those at high, low risk for events

Hyperbaric O2 Therapy Effective in Maxillary Osteoradionecrosis

Hyperbaric O<sub>2</sub> Therapy Effective in Maxillary Osteoradionecrosis

Positive clinical outcome with HBOT for 85.7 percent of patients with maxillary bone osteoradionecrosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »